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Background 
• Multi-phenotype genome-wide association studies (MP-GWAS) of 
correlated traits are more powerful than single-trait GWAS for locus 
discovery 
• We have previously developed a MP-GWAS method using ‘reverse 
regression’ approach in which genotype dosage is regressed on a linear 
combination of phenotypes, implemented into the software tool SCOPA and 
meta-analysis tool METASCOPA 1 
• There is no multi-phenotype method for epigenome-wide association 
analysis (MP-EWAS)  
 
Aims 
• To adapt the ‘reverse regression’ approach for epigenome-wide association 
analysis 
• To test the method on metabolic traits   
 
Material and Methods 
• Cohorts: Northern Finland Birth Cohorts 1966 (NFBC1966, N=635) and 1986 
(NFBC1986, N=346)  
• Epigenetic data: Illumina Infinium HumanMethylation450K BeadChip array 
• Phenotypic data:  fasting glucose (FG) and fasting insulin (FI) (rFG,FI=0.096) 
 
 
Flowchart of the analysis process: 
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Results 
• The strongest association signal (P=1.4×107) is observed for a methylation 
marker at chromosome 22:49,088,813, mapping to FAM19A5 gene  
• Single-trait EWAS results for the same marker: FI, P=0.13; FG, P=4.0×103 
• We also observe an association (P=9.84×103) with a marker at 
chromosome 21:43,656,587, which maps to ABCG1, an established BMI, 
measures of glucose metabolism, and incident type 2 diabetes methylation 
locus 
• Single-trait EWAS results for the same marker : FI, P=0.44; FG, P=8.25×103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Manhattan plot displaying log10(P-value) of association with FI and FG 
residuals in MP-EWAS meta-analysis for each methylation probe across the 
autosomal chromosomes. Insets show regional association plots for the ‘top hit’ at 
chr 22 and the established ABCG1 locus at chr 21. The regional plots were made 
using the comet() function from the Bioconductor package ‘coMET’. 
 
Summary and conclusions  
• We have successfully extended the multi-phenotype approach to 
methylation data 
 
• We observed an association at an established locus for metabolic 
traits, as well as at a novel locus which needs further validation 
 
• MP-EWAS with methylSCOPA is more powerful  than single-trait 
EWAS for multi-phenotype epigenetic effect detection 
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Figure 1. Geographic location of the NFBC1966 and 
NFBC1986.2 
Development of 
methylSCOPA 
and META-
methylSCOPA 
• Extend the SCOPA software to allow for methylation data 
as input  and to analyse methylation data analogous to 
genotype dosage data 
• Extend METASCOPA software for meta-analysis of MP-
EWAS results  
Methylation 
data 
preprocessing 
& quality 
control (QC) 
• Filter out unreliably detected methylation probes, and 
outlying individuals  using principal component [PC] 
scores 
• Subset quantile-normalize raw methylation signals 
• Transform to “beta” values, inverse-normal transform 
• Regress on PC scores ( batch effect removal)3 & 
‘Houseman estimates’4 ( leukocyte type composition 
correction) 
Phenotype data 
preprocessing & 
QC 
• Exclude non-fasting, pregnant, diabetic individuals 
• Natural log-transform FI 
• Regress FG & FI on sex, body mass index, fasting serum 
triglycerides & waist-hip ratio 
• Use resulting residuals in the MP-EWAS  
Cohort-specific 
analyses  in 
methylSCOPA  
• Model:  
Methylation probei  = FGres + ln(FI)res  +  ei,  
i=1,…,459k in NFBC1966 and i=1,…,466k in NFBC1986 
Meta-analysis   
• Use METAmethylSCOPA for MP-EWAS results 
• Use R packages metap and metafor for the meta-
analysis of the phenotypic/methylation correlation  
• Use P<1×107 to denote epigenome-wide significance 
Annotation • Map the results to CGCh37/hg19 
ABCG1 
